

VI. GLOSSARY

1. AAHS – Amorphous Aluminum Hydroxyphosphate Sulfate
2. AE – Adverse event
3. AIS – Cervical Adenocarcinoma in situ
4. CHMP – Committee for medical products for human use
5. CIN – Cervical Intraepithelial Neoplasia
6. CI – Confidence Interval
7. cLIA – Competitive Luminex Assay
8. EGL – External genital lesions
9. EMEA – European Medicines Agency
10. FAS – Full Analysis Set
11. FUTURE – Females United To Unilaterally Reduce Endo/Ectocervical Disease
12. HPV – Human Papilloma virus
13. HNRT – HPV-Naïve to the Relevant-HPV-Type
14. LEEP – Loop Electrosurgical Excision Procedure
15. LLOQ – Lower Limit Of Quantification
16. MAA – Marketing authorisation application
17. MAH – Marketing authorisation holder
18. MAW – Mid-Adult Women
19. mMU/ml – Milli-Merck Units per millilitre.
20. Pap – Papanicolaou's test
21. PCR – Polymerase chain reaction
22. PI – Persistent Infection
23. PL – Package Leaflet
24. PPE – Pre-protocol Efficacy
25. PPI – Per-Protocol immunogenicity
26. qHPV – Quadrivalent HPV vaccine
27. SIL – Squamous Intraepithelial Lesion
28. SPC – Summary of Product Characteristics
29. STD – Sexual transmitted diseases
30. VaIN – Vaginal intraepithelial neoplasia
31. VE – Vaccine efficacy
32. VIN – Vulvar intraepithelial neoplasia
33. VLP – Virus-like particle
34. YAW – Young Adult Woman
35. LR – Likelihood ratio
36. PPV – Positive predictive value.
37. MITT – Modified Intention to Treat-
38. SAES – Serious adverse events
39. PTS – Preferred terms
40. AES – Adverse events
41. ISI – Request for Supplementary information
42. FUM – Follow up measure